← Search another drug
PatientPulse · by PatientPartner
Cosentyx secukinumab
High confidence
~55 public patient pages analyzed: review-site content from Drugs.com (265+ reviews), forum discussions from Inspire, Spondylitis Association of America, and Psoriasis Association UK, patient blogs, and relevant clinical/news content. MyPsoriasisTeam member commentary referenced via site aggregation (617 comments on Cosentyx).
Executive intelligence
The signal that moves starts & adherence
52%Positive sentiment in discussion
158,767FDA adverse-event reports
40%Flagged serious
62%Reports name female patients
Skin-responders become vocal brand champions, but PsA patients rate Cosentyx nearly 2 points lower than PsO patients on Drugs.com (5.6 vs 7.2), signaling a critical unmet need in joint-domain messaging and support.
- Cosentyx delivers fast, dramatic skin clearance for most plaque psoriasis patients, generating strong advocacy, but joint-domain response is slower, more partial, and far less celebrated in public discourse.
- The loading-phase experience (weeks 1-5) is the single biggest adherence cliff: side effects peak, efficacy lags, and patients with prior biologic failures are primed to quit without peer reassurance.
- Insurance prior-authorization denials and mid-treatment formulary switches are a top-volume grievance that directly interrupts dosing and drives involuntary switching to Skyrizi or Taltz.
- An emerging GLP-1 co-therapy signal is active in the patient community, with Cosentyx users on axSpA and PsA independently seeking semaglutide or tirzepatide to counteract perceived weight gain and boost biologic response.